1. Introduction {#sec1}
===============

Single-nucleotide polymorphisms (SNP) are variations in single nucleotides that occur at specific positions in the genome and influence protein structure, gene splicing, transcription factor binding, messenger RNA degradation, or sequences of noncoding RNAs \[[@B1]\]. SNPs reportedly contribute to interindividual variability in susceptibility to common diseases such as cancer.

Matrix metalloproteinases (MMPs) are a group of proteolytic enzymes that can degrade extracellular matrix components, thereby affecting various physiological and pathological processes such as embryonic development, wound healing, arthritis, atherosclerosis, and tumor progression \[[@B2]\]. Increasing evidence shows that MMPs play significant roles in cancer development, including cell growth, differentiation, apoptosis, angiogenesis, invasion, and metastasis \[[@B3]\].

MMP1, a member of the MMP family, can degrade interstitial collagen types I, II, and III, clearing a path for cancer cells to invade matrix barriers and migrate through tissue stroma \[[@B4]\]. The *MMP1* gene is located at 11q22.3, and MMP1 expression can be regulated by the *MMP1* promoter. The gene polymorphism *MMP1*--1607 (1G\>2G) or rs1799750 in the *MMP1* promoter has been associated with increased susceptibility for various cancers \[[@B5], [@B6]\]. However, the results were controversial because of variations in cancer types and patient demographics. Therefore, we conducted this meta-analysis to further explore the association between *MMP1*--1607 (1G\>2G) polymorphism and cancer susceptibility.

2. Materials and Methods {#sec2}
========================

2.1. Identification and Eligibility of Studies {#sec2.1}
----------------------------------------------

We conducted a systematic search of literature published until December 2017 that investigated the association of *MMP1*--1607 (1G\>2G) polymorphism with cancer risks, through PubMed, Embase, ISI Web of Knowledge, and Google Scholar, using the terms "Matrix metalloproteinase-1 or MMP-1 or rs1799750," "polymorphism or variation or mutation or SNP," and "cancer or carcinoma or tumor or neoplasm." Only case--control studies with sufficient genotype distribution data to calculate odds ratios (ORs) with 95% confidence interval (CIs) in different gene models were included. Letters, case reports, animal studies, and reviews were excluded. When overlapping populations were included in different articles, only the publication with the largest sample size was selected.

2.2. Data Extraction {#sec2.2}
--------------------

Two investigators independently reviewed the articles to exclude irrelevant and overlapping studies. The following data were extracted from eligible publications: first author, published year, cancer type, country, ethnicity, control source, genotyping method, and genotype distribution. Any disagreements were resolved by discussion or by consultation with another investigator.

2.3. Statistical Analysis {#sec2.3}
-------------------------

The meta-analysis was conducted using SATAT (version 13.0). The Hardy--Weinberg equilibrium (HWE) for control groups was checked by the chi-square goodness-of-fit test (*P* \> 0.05) The associations between *MMP1*--1607 (1G\>2G) polymorphism and cancer risks were calculated by OR and 95% CI with the following models to avoid assuming only one suboptimal genetic model: an allele model (2G vs. 1G), a dominant model (2G2G/1G2G vs. 1G1G), and a recessive model (2G2G vs. 1G2G/1G1G). Subgroup analyses were performed by cancer type and ethnicity.

The heterogeneity of studies was assessed by *Q* test using *P* value and *I*^2^ value. A fixed-effects model was adopted when *Q* test indicated a lack of heterogeneity (*P* \> 0.05); otherwise, a random-effects model was used. We considered 0--40% of *I*^2^ value to indicate low heterogeneity, 30--60% to indicate moderate heterogeneity, 50--90% to indicate substantial heterogeneity, and 75--100% to indicate considerable heterogeneity. Publication bias was measured with funnel plots and Harbord\'s and Peter\'s tests.

3. Results {#sec3}
==========

3.1. Characteristics of Eligible Studies {#sec3.1}
----------------------------------------

The study selection procedure is shown in [Figure 1](#fig1){ref-type="fig"}. We included 77 articles with 21,327 cancer patients and 23,245 controls in this meta-analysis ([Table 1](#tab1){ref-type="table"}) \[[@B7]--[@B83]\]. Of these, 43 articles were conducted among Asian populations and 34 among Caucasian populations; 67 studies were hospital-based and 10 were population-based. Of the different genotyping methods used in these studies, 45 used polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), 18 used TaqMan real-time PCR, 8 used sequencing, and 6 used other methods. Sixteen of the 77 articles showed deviations from HWE in control groups.

3.2. Quantitative Analysis {#sec3.2}
--------------------------

The main results of this meta-analysis are listed in [Table 2](#tab2){ref-type="table"}. The association between the *MMP1*--1607 (1G\>2G) polymorphism and cancer risks was seen in the allele model (2G vs. 1G, OR: 1.174, 95% CI: 1.107--1.244; [Figure 2](#fig2){ref-type="fig"}), the dominant model (2G2G/1G2G vs. 1G1G, OR: 1.192, 95% CI: 1.090--1.303; [Figure 3](#fig3){ref-type="fig"}), and the recessive model (2G2G vs. 1G2G/1G1G, OR: 1.231, 95% CI: 1.141--1.329; [Figure 4](#fig4){ref-type="fig"}).

3.3. Risk by Cancer Type {#sec3.3}
------------------------

When we considered different cancer types, elevated risk was found in lung cancer in the allele model (2G vs. 1G, OR: 1.128, 95% CI: 1.002--1.268) and the dominant model (2G2G/1G2G vs. 1G1G, OR: 1.127, 95% CI: 1.005--1.264).

Significant association was also found in colorectal cancer in the allele model (2G vs. 1G, OR: 1.279, 95% CI: 1.087--1.505), the dominant model (2G2G/1G2G vs. 1G1G, OR: 1.281, 95% CI: 1.033--1.588), and the recessive model (2G2G vs. 1G2G/1G1G, OR: 1.368, 95% CI: 1.094--1.712).

Five articles addressed the *MMP1*--1607 polymorphism in nervous system cancers, including astrocytoma, glioblastoma, hypophyseal adenoma, and malignant gliomas. Significantly elevated risks were observed in all the three different models (2G vs. 1G, OR: 1.799, 95% CI: 1.493--2.168; 2G2G/1G2G vs. 1G1G, OR: 2.070, 95% CI: 1.474--2.906; and 2G2G vs. 1G2G/1G1G, OR: 1.935, 95% CI: 1.498--2.501).

In renal cancer, the association was found in the allele model (2G vs. 1G: OR: 1.351, 95% CI: 1.149--1.590) and the recessive model (2G2G vs. 1G2G/1G1G OR: 1.674, 95% CI: 1.351--2.073). In bladder cancer, only in the recessive model was significant association detected (2G2G vs. 1G2G/1G1G, OR: 1.739, 95% CI: 1.074--2.816).

Increased risk was also found in nasopharyngeal cancer in the allele model (2G vs. 1G, OR: 1.212, 95% CI: 1.067--1.377) and the recessive model (2G2G vs. 1G2G/1G1G, OR: 1.267, 95% CI: 1.074--1.488).

No relationship was observed in gastric cancer, oral cancer, ovarian cancer, breast cancer, prostate cancer, head and neck cancer, endometrial cancer, hepatocellular cancer, or esophageal cancer ([Table 2](#tab2){ref-type="table"}).

3.4. Risk by Ethnicity {#sec3.4}
----------------------

In the Asian population, the association between the variation and cancer risks was detected in the allele model (2G vs. 1G, OR: 1.228, 95% CI: 1.130--1.334), the dominant model (2G2G/1G2G vs. 1G1G, OR: 1.256, 95% CI: 1.084--1.456), and the recessive model (2G2G vs. 1G2G/1G1G, OR: 1.297, 95% CI: 1.176--1.431). In the Caucasian population, evaluated risk was also found in the allele model (2G vs. 1G, OR: 1.109, 95% CI: 1.023--1.202), the dominant model (2G2G/1G2G vs. 1G1G, OR: 1.126, 95% CI: 1.015--1.249), and the recessive model (2G2G vs. 1G2G/1G1G, OR: 1.431, 95% CI: 1.013--1.289). Although significant differences were observed in both Asian and Caucasian populations, the Asian population showed higher risk than the Caucasian for the allele, dominant model, or homozygous model, but showed a decreasing trend in the recessive model ([Table 2](#tab2){ref-type="table"}).

3.5. Heterogeneity and Sensitivity Analysis {#sec3.5}
-------------------------------------------

Heterogeneity was observed in overall analyses in all comparison models with *P* \< 0.05 and *I*^2^ range from 50.2% to 74.0% (indicating moderate or substantial heterogeneity). We therefore used the random-effects model. Sensitivity analysis to assess influence of individual studies showed no individual study to greatly affect the pooled OR.

3.6. Publication Bias {#sec3.6}
---------------------

The forest plot seemed to be symmetrical ([Figure 5](#fig5){ref-type="fig"}). Harbord\'s and Peter\'s tests revealed no statistical significance in publication bias (Harbord\'s: *P* = 0.093; Peter\'s: *P* = 0.153).

4. Discussion {#sec4}
=============

The *MMP1*--1607 (1G\>2G) polymorphism has been associated with increased transcription of *MMP1* due to an insert of a guanine base that creates a core-binding site for the EST family of transcription factors, which leads to increased susceptibility for tumor occurrence and progress. The significant association between the variation of *MMP1*--1607 (1G\>2G) with some cancer types has been reported by different meta-analyses \[[@B3], [@B4], [@B84]--[@B86]\].

In the current meta-analysis of 77 articles with 21,327 cancer patients and 23,245 controls, the *MMP1*--1607 (1G\>2G) polymorphism was a strong risk factor in various cancers. Although both Asian and Caucasian individuals with 2G alleles or 2G2G genotypes may be more susceptible to cancer development, several studies revealed significant associations in Asians, but not Caucasians \[[@B5], [@B6]\]. These discrepancies might be due to limited sample sizes. Moreover, the Asian population seemed to show increased risk compared with Caucasian populations when the allele or dominant models were adopted, whereas a decreasing trend was observed in a recessive model, which implies different susceptibilities.

The association was found in lung, colorectal, nervous system, renal, bladder, and nasopharyngeal cancers, but not gastric, oral, ovarian, breast, prostate, head-and-neck, endometrial, hepatocellular, or esophageal cancers, which indicates that the variation plays different roles in various cancers, in accordance with pervious meta-analyses \[[@B4], [@B85], [@B87], [@B88]\]. However, these papers only focused on single types of cancer or one specific ethnicity. Our meta-analysis included all the cancers, analyzed the overall pooled OR, and performed subgroup analyses. Our findings imply a complex relationship between cancer susceptibility and gene variation, influenced by cancer sites and ethnicities.

Recently, the functional studies of SNPs have moved fast. For instance, a study reported that a missense variant rs149418249 in the TPP1 gene confers colorectal cancer risk by interrupting TPP1--TIN2 interaction and influencing telomere length \[[@B89]\]. An expression quantitative trait locus-based analysis revealed that a mutation rs27437, residing in the upstream of SLC22A5, can affect colorectal cancer risk by regulating SLC22A5 expression \[[@B90]\]. Another article reported that a TCF7L2 missense variant rs138649767 associates with colorectal cancer risk by interacting with a GWAS-identified regulatory variant rs698326 in the MYC enhancer \[[@B91]\]. However, the biological mechanisms of functional SNPs still remain challenging. Therefore, further studies are required to promulgate the real functions by which the MMP1--1607 (1G\>2G) polymorphism may influence cancer susceptibility and progression.

Our study had some limitations. First, moderate or substantial heterogeneity was detected between studies, which was not significantly decreased by subgroup analysis. When all variations were included in the meta-regression analysis, no obvious factors were detected. More subgroup analyses should be performed, based on factors such as tobacco or alcohol consumption. This conclusion should be interpreted with caution. Second, this analysis was performed with candidate gene strategy in which the MMP1--1607 (1G\>2G) polymorphism was selected for study based on a priori knowledge of the gene\'s biological functional impact on the trait or disease in question \[[@B92]\]. Genome-wide association studies (GWAS) which scan the entire genome for genetic variation include immense amounts of SNPs. Published papers usually reported those SNPs with highly statistical significance (usually *P* \< 10^−6^). We have retrieved literature through PubMed in order to search the evidence of association between the MMP1--1607 (1G\>2G) polymorphism and cancer risks in GWAS results \[[@B92], [@B93]\]. However, we did not acquire any positive findings. We speculate that ethnic discrepancy, population stratification, and different standards of statistical significance might lead to negative findings in GWAS. Third, due to the innate shortage of case--control designed studies, the quantity of studies was limited. Third, gene--gene and gene--environment interactions should be considered in analyses of the effects of genes. Fourth, more original papers with large sample sizes were required due to lack of eligible studies in specific cancers in this analysis.

5. Conclusions {#sec5}
==============

In conclusion, an association between the *MMP1*--1607 (1G\>2G) polymorphism and cancer risks was detected in both Asians and Caucasians. After stratification by cancer types, associations were found for lung cancer, colorectal cancer, nervous system cancer, renal cancer, bladder cancer, and nasopharyngeal cancer. More original studies with larger sample size are required for future analysis.
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###### 

The main characteristics of studies included in the meta-analysis.

  Author                               Year   Cancer type             Country    Ethnicity   Control   Genotype     *N* of case   *N* of control   HWE (*P*)
  ------------------------------------ ------ ----------------------- ---------- ----------- --------- ------------ ------------- ---------------- -----------
  Kanamori et al. \[[@B7]\]            1999   Ovarian cancer          Japan      Asian       HB        PCR-RFLP     163           150              0.033
  Biondi et al. \[[@B8]\]              2000   Other cancer            Italy      Caucasian   HB        TaqMan       160           164              0.813
  Nishioka et al. \[[@B9]\]            2000   Endometrial cancer      Japan      Asian       HB        Sequencing   100           150              0.033
  Ye et al. \[[@B10]\]                 2001   Cutaneous melanoma      England    Caucasian   HB        TaqMan       139           132              0.849
  Zhu et al. \[[@B11]\]                2001   Lung cancer             America    Caucasian   HB        PCR-RFLP     456           451              0.028
  Ghilardi et al. \[[@B12]\]           2002   Breast cancer           America    Caucasian   HB        Sequencing   86            110              0.652
  Hinoda et al. \[[@B13]\]             2002   Colorectal cancer       Japan      Asian       PB        PCR-RFLP     101           127              0.949
  Hirata et al. \[[@B14]\]             2003   Renal cell cancer       Japan      Asian       HB        Sequencing   119           210              0.993
  Nishioka et al. \[[@B15]\]           2003   Endometrial cancer      Japan      Asian       HB        Sequencing   109           150              0.033
  Wenham et al. \[[@B16]\]             2003   Ovarian cancer          America    Caucasian   PB        TaqMan       311           387              0.536
  Hashimoto et al. \[[@B17]\]          2004   Head and neck cancer    Japan      Asian       HB        PCR-RFLP     140           223              0.852
  Hirata et al. \[[@B18]\]             2004   Renal cell cancer       Japan      Asian       PB        PCR-RFLP     156           230              0.871
  Lin et al. \[[@B19]\]                2004   Oral cancer             Taiwan     Asian       HB        Sequencing   121           147              0.336
  Matsumura et al. \[[@B20]\]          2004   Gastric cancer          Japan      Asian       HB        PCR-RFLP     215           166              0.432
  Zinzindohoué et al. \[[@B21]\]       2004   Head and neck cancer    France     Caucasian   HB        PCR-RFLP     125           249              0.978
  Fang et al. \[[@B22]\]               2005   Lung cancer             China      Asian       HB        PCR-RFLP     243           350              0.000
  Jin et al. \[[@B23]\]                2005   Gastric cancer          China      Asian       HB        PCR-RFLP     417           350              0.000
  Ju et al. \[[@B24]\]                 2005   Cervical cancer         Korea      Asian       HB        TaqMan       232           332              0.695
  Lai et al. \[[@B25]\]                2005   Cervical cancer         Taiwan     Asian       HB        Other        197           197              1.000
  McCready et al. \[[@B26]\]           2005   Glioblastoma            America    Caucasian   HB        PCR-RFLP     81            57               0.916
  Cao and Li \[[@B27]\]                2006   Oral cancer             China      Asian       HB        PCR-RFLP     96            120              0.657
  Elander et al. \[[@B28]\]            2006   Colorectal cancer       Sweden     Caucasian   HB        Other        127           208              0.918
  Kader et al. \[[@B29]\]              2006   Bladder cancer          America    Caucasian   HB        TaqMan       556           555              0.565
  Li et al. \[[@B30]\]                 2006   Ovarian cancer          China      Asian       HB        PCR-RFLP     122           151              0.008
  Lièvre et al. \[[@B31]\]             2006   Colorectal cancer       France     Caucasian   HB        Other        591           561              0.900
  O-charoenrat et al. \[[@B32]\]       2006   Head and neck cancer    Thailand   Asian       HB        PCR-RFLP     300           300              0.988
  Su et al. \[[@B33]\]                 2006   Lung cancer             America    Caucasian   PB        TaqMan       2014          1323             0.597
  Sugimoto et al. \[[@B34]\]           2006   Endometrial cancer      Japan      Asian       HB        PCR-RFLP     107           213              0.768
  Xu et al. \[[@B35]\]                 2006   Colorectal cancer       China      Asian       HB        Other        126           126              0.938
  Albayrak et al. \[[@B36]\]           2007   Prostate cancer         Turkey     Caucasian   HB        PCR-RFLP     55            43               0.000
  Ju et al. \[[@B37]\]                 2007   Ovarian cancer          Korea      Asian       HB        TaqMan       133           332              0.695
  Lei et al. \[[@B38]\]                2007   Breast cancer           Sweden     Caucasian   PB        TaqMan       954           947              0.151
  Lu et al. \[[@B39]\]                 2007   Other cancer            China      Asian       HB        PCR-RFLP     221           366              0.000
  Nasr et al. \[[@B40]\]               2007   Nasopharyngeal cancer   Tunisia    Caucasian   HB        PCR-RFLP     174           171              0.091
  Nishizawa et al. \[[@B41]\]          2007   Oral cancer             Japan      Asian       HB        TaqMan       170           164              0.493
  Piccoli et al. \[[@B42]\]            2007   Renal cell carcinoma    Brazil     Caucasian   PB        PCR-RFLP     99            118              1.000
  Vairaktaris et al. \[[@B43]\]        2007   Oral cancer             Greek      Caucasian   HB        PCR-RFLP     156           141              0.276
  Woo et al. \[[@B44]\]                2007   Colorectal cancer       Korea      Asian       HB        PCR-RFLP     185           304              0.488
  Zhai et al. \[[@B45]\]               2007   Hepatocellular cancer   China      Asian       HB        Sequencing   431           479              0.559
  Zhou et al. \[[@B46]\]               2007   Nasopharyngeal cancer   China      Caucasian   PB        Sequencing   829           759              0.634
  Dos Reis et al. \[[@B47]\]           2008   Prostate cancer         Brazil     Caucasian   PB        TaqMan       100           100              0.293
  González-Arriaga et al. \[[@B48]\]   2008   Lung cancer             Spain      Caucasian   HB        PCR-RFLP     501           510              0.934
  Kouhkan et al. \[[@B49]\]            2008   Colorectal cancer       Iran       Asian       HB        PCR-RFLP     150           100              0.935
  Shimizu et al. \[[@B50]\]            2008   Tongue cancer           Japan      Asian       HB        TaqMan       69            91               0.585
  Tasci et al. \[[@B51]\]              2008   Bladder cancer          Turkey     Caucasian   HB        PCR-RFLP     102           94               0.740
  Bradbury et al. \[[@B52]\]           2009   Esophageal cancer       America    Caucasian   HB        TaqMan       313           450              0.508
  de Lima et al. \[[@B53]\]            2009   Colorectal cancer       Brazil     Caucasian   HB        PCR-RFLP     108           108              0.258
  dos Reis et al. \[[@B54]\]           2009   Prostate cancer         Brazil     Caucasian   HB        TaqMan       100           100              0.293
  Ricketts et al. \[[@B55]\]           2009   Renal cell cancer       Polish     Caucasian   HB        TaqMan       323           314              0.847
  Srivastava et al. \[[@B56]\]         2010   Bladder cancer          India      Asian       HB        PCR-RFLP     200           200              0.190
  Tsuchiya et al. \[[@B57]\]           2009   Prostate cancer         Japan      Asian       PB        Sequencing   283           251              0.285
  Vairaktaris et al. \[[@B58]\]        2009   Oral cancer             Greek      Caucasian   HB        PCR-RFLP     156           141              0.276
  Altaş et al. \[[@B59]\]              2010   Other cancer            Turkey     Caucasian   HB        PCR-RFLP     30            30               0.195
  Chaudhary et al. \[[@B60]\]          2010   Head and neck cancer    India      Asian       HB        PCR-RFLP     422           426              0.240
  Fang et al. \[[@B61]\]               2010   Colorectal cancer       China      Asian       HB        PCR-RFLP     237           252              0.683
  Okamoto et al. \[[@B62]\]            2010   Hepatocellular cancer   Japan      Asian       HB        PCR-RFLP     91            82               0.009
  Hart et al. \[[@B63]\]               2011   Lung cancer             Norway     Caucasian   PB        TaqMan       436           434              0.218
  Liu et al. \[[@B64]\]                2011   Lung cancer             China      Asian       HB        PCR-RFLP     825           825              0.924
  Malik et al. \[[@B65]\]              2011   Glioblastoma            India      Asian       HB        PCR-RFLP     110           150              0.433
  Wang et al. \[[@B66]\]               2011   Cutaneous melanoma      America    Caucasian   HB        TaqMan       864           849              0.940
  Cheung et al. \[[@B67]\]             2012   Esophageal cancer       Canada     Caucasian   HB        TaqMan       309           279              0.974
  Enewold et al. \[[@B68]\]            2012   Lung cancer             America    Caucasian   HB        Other        71            147              0.743
  Fakhoury et al. \[[@B69]\]           2012   Lung cancer             Lebanon    Caucasian   HB        PCR-RFLP     41            51               0.218
  Wieczorek et al. \[[@B70]\]          2013   Bladder cancer          Poland     Caucasian   HB        TaqMan       240           199              0.022
  Brzóska et al. \[[@B71]\]            2014   Lung cancer             Poland     Caucasian   HB        PCR-RFLP     53            54               0.264
  Dedong et al. \[[@B72]\]             2014   Gastric cancer          China      Asian       HB        Other        422           428              0.546
  Devulapalli et al. \[[@B73]\]        2014   Gastric cancer          India      Asian       HB        PCR-RFLP     166           202              0.000
  Dey et al. \[[@B74]\]                2014   Gastric cancer          India      Caucasian   HB        PCR-RFLP     145           145              0.850
  Guan et al. \[[@B75]\]               2014   Esophageal cancer       China      Asian       HB        PCR-RFLP     132           132              0.989
  Kawal et al. \[[@B76]\]              2016   Breast cancer           Taiwan     Asian       HB        PCR-RFLP     1232          1232             0.004
  Pei et al. \[[@B77]\]                2016   Other cancer            Taiwan     Asian       HB        PCR-RFLP     266           266              0.258
  Su et al. \[[@B78]\]                 2016   Breast cancer           Taiwan     Asian       HB        PCR-RFLP     1232          1232             0.004
  Sun et al. \[[@B79]\]                2016   Oral cancer             Taiwan     Asian       HB        PCR-RFLP     788           956              0.029
  Tsai et al. \[[@B80]\]               2016   Nasopharyngeal cancer   Taiwan     Asian       HB        PCR-RFLP     176           352              0.278
  Lai et al. \[[@B81]\]                2017   Hepatocellular cancer   Taiwan     Asian       HB        PCR-RFLP     298           889              0.008
  Padala et al. \[[@B82]\]             2017   Breast cancer           India      Asian       HB        PCR-RFLP     300           300              0.015
  Yang et al. \[[@B83]\]               2017   Gastric cancer          Taiwan     Asian       HB        PCR-RFLP     121           363              0.131

HWE: Hardy--Weinberg equilibrium.

###### 

Stratified analyses of MMP1--1607 (1G\>2G) polymorphism on cancer risks by random-effects model.

                           *n*   2g vs. 1g   2g2g--1g2g vs. 1g1g   2g2g vs. 1g1g--1g2g                                                                                           
  ------------------------ ----- ----------- --------------------- --------------------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- -------
  Overall                  77    1.174       1.107                 1.244                 0.000   74.0%   1.192   1.090   1.303   0.000   62.4%   1.231   1.141   1.329   0.000   67.5%
  Cancer types                                                                                                                                                                   
   Lung cancer             9     1.128       1.002                 1.269                 0.006   63.1%   1.127   1.005   1.264   0.365   8.4%    1.153   0.953   1.395   0.002   68.1%
   Colorectal cancer       8     1.279       1.087                 1.505                 0.035   53.6%   1.281   1.033   1.588   0.365   8.5%    1.368   1.094   1.712   0.041   52.1%
   Gastric cancer          6     1.106       0.964                 1.268                 0.165   36.3%   1.221   0.884   1.687   0.061   52.6%   1.121   0.967   1.300   0.448   0.0%
   Oral cancer             6     1.121       0.849                 1.481                 0.000   81.8%   1.254   0.790   1.991   0.001   75.9%   1.108   0.807   1.521   0.003   72.3%
   Nervous system cancer   5     1.799       1.493                 2.168                 0.869   0.0%    2.070   1.474   2.906   0.438   0.0%    1.935   1.498   2.501   0.475   0.0%
   Ovarian cancer          4     1.022       0.888                 1.176                 0.845   0.0%    1.090   0.769   1.545   0.174   39.7%   1.013   0.823   1.247   0.417   0.0%
   Breast cancer           4     1.194       0.904                 1.576                 0.000   89.6%   1.352   0.906   2.017   0.000   84.9%   1.149   0.809   1.632   0.000   84.7%
   Renal cancer            4     1.351       1.149                 1.590                 0.328   12.8%   1.179   0.898   1.547   0.829   0.0%    1.674   1.351   2.073   0.580   0.0%
   Bladder cancer          4     1.437       0.960                 2.152                 0.000   89.2%   1.349   0.771   2.360   0.001   83.1%   1.739   1.074   2.816   0.001   81.7%
   Prostate cancer         4     0.932       0.485                 1.791                 0.000   90.3%   1.136   0.493   2.616   0.001   82.5%   0.780   0.375   1.623   0.001   82.3%
   Head and neck cancer    4     0.958       0.595                 1.543                 0.000   92.6%   0.678   0.388   1.186   0.001   81.1%   1.071   0.539   2.219   0.000   92.4%
   Endometrial cancer      3     1.147       0.756                 1.741                 0.020   74.4%   1.312   0.492   3.497   0.005   81.0%   1.091   0.807   1.476   0.320   12.3%
   Nasopharyngeal cancer   3     1.212       1.067                 1.377                 0.340   7.4%    1.299   0.996   1.696   0.319   12.5%   1.265   1.074   1.488   0.535   0.0%
   Hepatocellular cancer   3     0.995       0.875                 1.131                 0.890   0.0%    0.816   0.631   1.055   0.333   9.0%    1.118   0.932   1.341   0.428   0.0%
   Esophageal cancer       3     1.189       0.899                 1.572                 0.039   69.1%   1.321   0.908   1.922   0.138   49.5%   1.260   0.866   1.835   0.080   60.4%
   Other cancers           7     1.172       1.010                 1.360                 0.043   53.8%   1.128   0.903   1.410   0.167   34.2%   1.278   1.038   1.573   0.073   48.0%
  Ethnicity                                                                                                                                                                      
   Asian                   43    1.228       1.130                 1.334                 0.009   75.2%   1.256   1.084   1.456   0.000   68.9%   1.297   1.176   1.431   0.000   66.4%
   Caucasian               34    1.109       1.023                 1.202                 0.009   71.2%   1.126   1.015   1.249   0.000   50.1%   1.431   1.013   1.289   0.000   67.2%

*n*: number of comparison; *P*: *P* value of *Q* test for heterogeneity test; UCI: upper limit of the 95% confidence interval; LCI: lower limit of the 95% confidence interval.

[^1]: Academic Editor: Michael Hawkes
